Integra LifeSciences Obtains FDA Approval for Cardiac Application of CUSA Clarity System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy IART?
Source: NASDAQ.COM
FDA Clearance: Integra LifeSciences received U.S. FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System, expanding its use to cardiac surgery for debridement during valve replacement and repair procedures.
Existing Approvals: The CUSA Clarity system is already approved for various surgical fields, including neurosurgery and orthopedic surgery, where it aids in the fragmentation and aspiration of soft and hard tissues.
Significance of Clearance: This new clearance is a significant milestone, allowing for the application of ultrasonic aspiration in delicate cardiovascular surgeries, supported by sufficient safety and performance data.
Upcoming Showcase: Integra will present the CUSA Clarity system at the American Association for Thoracic Surgeon Mitral Valve Conclave in New York City on December 11-12, 2025, emphasizing its expanded role in cardiac care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IART?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IART
Wall Street analysts forecast IART stock price to rise
6 Analyst Rating
0 Buy
2 Hold
4 Sell
Moderate Sell
Current: 10.430
Low
10.00
Averages
12.33
High
14.00
Current: 10.430
Low
10.00
Averages
12.33
High
14.00
About IART
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Integra LifeSciences Q4 2025 Earnings Call Highlights
- Financial Performance Exceeds Expectations: Integra LifeSciences reported $435 million in revenue and adjusted EPS of $0.83 for Q4 2025, both surpassing the midpoint of guidance, indicating robust performance amid a 1.7% year-over-year revenue decline.
- Strategic Transformation Progress: The company implemented a new operating model to reduce complexity and enhance efficiency, launching a supply chain control tower that provides visibility into key operational metrics across its global network, aimed at improving supply chain reliability and responsiveness to support future growth.
- Product Relaunch Strategy: The early relaunch of PriMatrix and Durepair through a dual sourcing strategy is underway, while the ongoing build-out of the Braintree facility is expected to support the return of SurgiMend to the market in Q4 2026, showcasing the company's proactive approach to product innovation and market adaptability.
- Cautiously Optimistic Outlook: The CFO projected 2026 revenues between $1.66 billion and $1.7 billion, reflecting modest growth expectations of 1.6% to 4.1%, despite tariff impacts and market uncertainties, with the company maintaining confidence in its long-term growth prospects.
See More
Integra LifeSciences Reports Q4 Loss Amid Revenue Decline
- Financial Performance Decline: Integra LifeSciences reported a loss of $1.70 million in Q4, translating to a loss of $0.02 per share, compared to a profit of $19.44 million or $0.25 per share in the same quarter last year, indicating a significant decline in profitability.
- Operating Income Reduction: Operating income fell from $35.63 million a year earlier to $23.04 million, reflecting pressures on cost control and market competition, which may impact future investment decisions.
- Slight Revenue Decrease: Total revenue edged down 1.7% from $442.65 million in the prior-year quarter to $434.93 million, suggesting weak market demand that could affect the company's future growth outlook.
- Cautious Future Outlook: Integra expects full-year 2026 revenue between $1.662 billion and $1.702 billion, representing growth of 1.6% to 4.1%, while forecasting Q1 revenue between $375 million and $390 million, indicating a cautious stance towards the short-term market environment.
See More
Integra LifeSciences Q4 Earnings Exceed Expectations
- Earnings Beat: Integra LifeSciences reported a Q4 non-GAAP EPS of $0.83, exceeding expectations by $0.03, indicating strong profitability and investor confidence in the company's performance.
- Slight Revenue Decline: The company posted Q4 revenue of $434.9 million, a 1.7% year-over-year decline; however, it surpassed analyst expectations by $52,800, demonstrating resilience in a competitive market.
- Positive Market Reaction: Following the earnings release, the market reacted positively, with increased investor confidence in Integra's growth potential likely driving stock price appreciation.
- Importance of Strategic Execution: At the upcoming J.P. Morgan Healthcare Conference, the company will showcase its strategic plans, emphasizing the critical role of execution in realizing growth potential, reflecting management's clear vision for future development.
See More
Integra LifeSciences to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Integra LifeSciences Holdings Corporation is set to announce its Q4 2023 earnings on February 26 before market open, with a consensus EPS estimate of $0.80, reflecting a 17.5% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The company anticipates Q4 revenue of $429.62 million, down 2.9% year-over-year, indicating increased market competition and fluctuations in product demand, which could affect future growth strategies.
- Historical Performance Review: Over the past two years, Integra LifeSciences has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, demonstrating a degree of stability and adaptability in its financial performance.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and one downward revision, reflecting analysts' cautious outlook on the company's future performance.
See More
Integra LifeSciences to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Integra LifeSciences is set to announce its fourth quarter and full year 2025 financial results on February 26, 2026, prior to market open, which is expected to provide investors with critical performance metrics and future outlook.
- Management Conference Call: Following the earnings release, the management team will host a conference call at 8:30 a.m. ET, aimed at communicating financial results and company strategy to investors, thereby enhancing transparency and investor confidence.
- Live Webcast Availability: The conference call will be available via live webcast on the company's investor section, ensuring that global investors can access real-time information, thus improving interaction between the company and its investors.
- Replay Feature: After the call, a replay will be accessible on the company's website, allowing investors who could not participate live to obtain key information, further enhancing information accessibility and transparency.
See More
Integra LifeSciences Faces Recall Due to Packaging Defects Linked to 11 Serious Injuries
- FDA Alert: The FDA has issued an early alert regarding potentially high-risk issues with Integra LifeSciences' MediHoney wound and burn care products, citing packaging and production failures that could lead to infection and compromise patient safety.
- Product Recall: Integra has notified customers to immediately cease the use of all MediHoney wound and burn products and specific lots of CVS Wound Gel, ensuring these products are removed from clinical settings to prevent further harm.
- Injury Reports: As of December 19, 2025, Integra reported 11 serious injuries linked to MediHoney products and three serious injuries associated with CVS Wound Gel, highlighting the severity of safety concerns despite no reported fatalities.
- Distributor Instructions: Integra instructed distributors to halt further distribution of affected products and manage customer communications directly, ensuring that impacted products are properly handled, reflecting the company's commitment to customer safety.
See More
Integra LifeSciences Q4 2025 Earnings Call Highlights
- Financial Performance Exceeds Expectations: Integra LifeSciences reported $435 million in revenue and adjusted EPS of $0.83 for Q4 2025, both surpassing the midpoint of guidance, indicating robust performance amid a 1.7% year-over-year revenue decline.
- Strategic Transformation Progress: The company implemented a new operating model to reduce complexity and enhance efficiency, launching a supply chain control tower that provides visibility into key operational metrics across its global network, aimed at improving supply chain reliability and responsiveness to support future growth.
- Product Relaunch Strategy: The early relaunch of PriMatrix and Durepair through a dual sourcing strategy is underway, while the ongoing build-out of the Braintree facility is expected to support the return of SurgiMend to the market in Q4 2026, showcasing the company's proactive approach to product innovation and market adaptability.
- Cautiously Optimistic Outlook: The CFO projected 2026 revenues between $1.66 billion and $1.7 billion, reflecting modest growth expectations of 1.6% to 4.1%, despite tariff impacts and market uncertainties, with the company maintaining confidence in its long-term growth prospects.
See More
Integra LifeSciences Reports Q4 Loss Amid Revenue Decline
- Financial Performance Decline: Integra LifeSciences reported a loss of $1.70 million in Q4, translating to a loss of $0.02 per share, compared to a profit of $19.44 million or $0.25 per share in the same quarter last year, indicating a significant decline in profitability.
- Operating Income Reduction: Operating income fell from $35.63 million a year earlier to $23.04 million, reflecting pressures on cost control and market competition, which may impact future investment decisions.
- Slight Revenue Decrease: Total revenue edged down 1.7% from $442.65 million in the prior-year quarter to $434.93 million, suggesting weak market demand that could affect the company's future growth outlook.
- Cautious Future Outlook: Integra expects full-year 2026 revenue between $1.662 billion and $1.702 billion, representing growth of 1.6% to 4.1%, while forecasting Q1 revenue between $375 million and $390 million, indicating a cautious stance towards the short-term market environment.
See More
Integra LifeSciences Q4 Earnings Exceed Expectations
- Earnings Beat: Integra LifeSciences reported a Q4 non-GAAP EPS of $0.83, exceeding expectations by $0.03, indicating strong profitability and investor confidence in the company's performance.
- Slight Revenue Decline: The company posted Q4 revenue of $434.9 million, a 1.7% year-over-year decline; however, it surpassed analyst expectations by $52,800, demonstrating resilience in a competitive market.
- Positive Market Reaction: Following the earnings release, the market reacted positively, with increased investor confidence in Integra's growth potential likely driving stock price appreciation.
- Importance of Strategic Execution: At the upcoming J.P. Morgan Healthcare Conference, the company will showcase its strategic plans, emphasizing the critical role of execution in realizing growth potential, reflecting management's clear vision for future development.
See More
Integra LifeSciences to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Integra LifeSciences Holdings Corporation is set to announce its Q4 2023 earnings on February 26 before market open, with a consensus EPS estimate of $0.80, reflecting a 17.5% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The company anticipates Q4 revenue of $429.62 million, down 2.9% year-over-year, indicating increased market competition and fluctuations in product demand, which could affect future growth strategies.
- Historical Performance Review: Over the past two years, Integra LifeSciences has beaten EPS estimates 63% of the time and revenue estimates 63% of the time, demonstrating a degree of stability and adaptability in its financial performance.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates also saw no upward revisions and one downward revision, reflecting analysts' cautious outlook on the company's future performance.
See More
Integra LifeSciences to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Integra LifeSciences is set to announce its fourth quarter and full year 2025 financial results on February 26, 2026, prior to market open, which is expected to provide investors with critical performance metrics and future outlook.
- Management Conference Call: Following the earnings release, the management team will host a conference call at 8:30 a.m. ET, aimed at communicating financial results and company strategy to investors, thereby enhancing transparency and investor confidence.
- Live Webcast Availability: The conference call will be available via live webcast on the company's investor section, ensuring that global investors can access real-time information, thus improving interaction between the company and its investors.
- Replay Feature: After the call, a replay will be accessible on the company's website, allowing investors who could not participate live to obtain key information, further enhancing information accessibility and transparency.
See More
Integra LifeSciences Faces Recall Due to Packaging Defects Linked to 11 Serious Injuries
- FDA Alert: The FDA has issued an early alert regarding potentially high-risk issues with Integra LifeSciences' MediHoney wound and burn care products, citing packaging and production failures that could lead to infection and compromise patient safety.
- Product Recall: Integra has notified customers to immediately cease the use of all MediHoney wound and burn products and specific lots of CVS Wound Gel, ensuring these products are removed from clinical settings to prevent further harm.
- Injury Reports: As of December 19, 2025, Integra reported 11 serious injuries linked to MediHoney products and three serious injuries associated with CVS Wound Gel, highlighting the severity of safety concerns despite no reported fatalities.
- Distributor Instructions: Integra instructed distributors to halt further distribution of affected products and manage customer communications directly, ensuring that impacted products are properly handled, reflecting the company's commitment to customer safety.
See More
